First launch for Novo Nordisk's Xultophy

Novo Nordisk's new combination diabetes product Xultophy has reached its first market, Switzerland.

Novo Nordisk's new combination diabetes product Xultophy has reached its first market, Switzerland.

The combination of Novo's basal insulin Tresiba (insulin degludec) and its GLP-1 analog Victoza (liraglutide) is intended for use in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip